


**Amendments to the Claims**

1. (Previously Presented) A compound of formula I:



(I)

wherein:

Ar<sup>1</sup> is a cyclic group optionally substituted with one to five groups selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkylaryl, phenyl, aryl, -O-aryl, heteroaryl, cycloalkyl, C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, cyano, -(CH<sub>2</sub>)<sub>n</sub>NR<sup>6</sup>R<sup>6</sup>, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkoxy, halo, (CH<sub>2</sub>)<sub>n</sub>COR<sup>6</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>n</sub>C(O)NR<sup>6</sup>R<sup>6</sup>, heterocyclic, and C<sub>1</sub>-C<sub>8</sub> alkylheterocyclic; wherein the cycloalkyl, phenyl, aryl, and heterocyclic groups are each optionally substituted with one to three groups independently selected from hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkoxy, C<sub>1</sub>-C<sub>8</sub> alkyl, halo, C<sub>1</sub>-C<sub>8</sub> haloalkyl, nitro, cyano, amino, carboxamido, phenyl, aryl, alkylheterocyclic, heterocyclic, and oxo;

L<sup>1</sup> is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -SCH<sub>2</sub>-, -OCH<sub>2</sub>-, -CH<sub>2</sub>SCH<sub>2</sub>-, -CH<sub>2</sub>OCH<sub>2</sub>-, -OCH<sub>2</sub>CH<sub>2</sub>SCH<sub>2</sub>-, or a divalent linker represented by the formula X<sub>2</sub>-(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>-X<sub>3</sub> where X<sub>2</sub> is attached to Ar<sup>1</sup> and X<sub>3</sub> is attached to Ar<sup>2</sup> wherein R<sup>3</sup> and R<sup>4</sup> are independently selected from a bond, hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkylene, C<sub>2</sub>-C<sub>8</sub> alkynyl, phenyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkylaryl; wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substituents independently selected from oxo, nitro, cyano, C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, halo, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> haloalkyl, (CH<sub>2</sub>)<sub>n</sub>C(O)R<sup>6</sup>, and (CH<sub>2</sub>)<sub>n</sub>CONR<sup>6</sup>R<sup>6</sup>;

X<sub>2</sub> is independently oxygen, -CH, -CONH(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>, -NHCO(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>, -(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>, -CHR<sup>6</sup>, -NR<sup>5</sup>, S, SO, SO<sub>2</sub>, -O(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>, or -S(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>;

X<sub>3</sub> is independently oxygen, -C, -CH, -CHR<sup>6</sup>, -(CR<sup>3</sup>R<sup>4</sup>)<sub>m</sub>, -NR<sup>5</sup>, S, SO, or SO<sub>2</sub>;

Ar<sup>2</sup> is a 5-member monocyclic heterocyclic aromatic group or positional isomer thereof, having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and wherein Ar<sup>2</sup> is optionally substituted with one to three substituents independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkylaryl, phenyl, aryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>1</sub>-C<sub>8</sub> alkylcycloalkyl, cyano, C<sub>1</sub>-C<sub>8</sub> haloalkyl, halo,

$(\text{CH}_2)_n\text{C}(\text{O})\text{R}^6$ ,  $(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^6$ ,  $(\text{CH}_2)_n\text{NR}^5\text{SO}_2\text{R}^6$ ,  $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$ , and  $\text{C}_1\text{-C}_8$  alkylheterocyclic;

$\text{Ar}^3$  is an optionally substituted bicyclic aromatic or non-aromatic group;

$\text{L}^2$  is  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$  or a divalent linker represented by the formula  $\text{X}_4-(\text{CR}^3\text{R}^4)_m-\text{X}_5$ ;

wherein  $\text{X}_4$  is selected from the group consisting of C,  $-\text{CH}$ ,  $\text{CHR}^6$ ,  $-\text{CO}$ , O,  $-\text{NR}^5$ ,  $-\text{NC}(\text{O})-$ ,  $-\text{NC}(\text{S})$ ,  $-\text{C}(\text{O})\text{NR}^5-$ ,  $-\text{NR}^6\text{C}(\text{O})\text{NR}^6$ ,  $-\text{NR}^6\text{C}(\text{S})\text{NR}^6$ ,  $-\text{SO}_2\text{NR}^7$ ,  $-\text{NRSO}_2\text{R}^7$ , and  $-\text{NR}^6\text{C}(\text{NR}^5)\text{NR}^6$ ;

$\text{X}_5$  is selected from the group consisting of O,  $-\text{CH}_2$ ,  $-\text{CH}$ ,  $-\text{O}(\text{CR}^3\text{R}^4)_m$ ,  $\text{NR}^3(\text{CR}^3\text{R}^4)_m$ , SO,  $\text{SO}_2$ , S, and  $\text{SCH}_2$ ; wherein the group  $\text{X}_4-(\text{CR}^3\text{R}^4)_m-\text{X}_5$  imparts stability to the compound of formula (1) and may be a saturated or unsaturated chain or divalent linker;

$\text{R}^1$  and  $\text{R}^2$  are independently hydrogen,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_3\text{-C}_8$  cycloalkyl,  $\text{C}_1\text{-C}_8$  alkylaryl,  $-\text{C}(\text{O})\text{C}_1\text{-C}_8$  alkyl,  $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$  alkyl,  $\text{C}_1\text{-C}_8$  alkylcycloalkyl,  $(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^5$ ,  $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^5$ ,  $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$ , and  $(\text{CH}_2)_n\text{NSO}_2\text{R}^5$ ; wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups independently selected from  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl, phenyl, and alkylaryl; and wherein  $\text{R}^1$  and  $\text{R}^2$  may combine together, and with the nitrogen atom to which they are attached or with 0, 1, 2 or 3 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have 1, or 2 substituents independently selected from  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_3\text{-C}_8$  cycloalkyl,  $\text{C}_1\text{-C}_8$  alkylaryl,  $-\text{C}(\text{O})\text{C}_1\text{-C}_8$  alkyl,  $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$  alkyl,  $\text{C}_1\text{-C}_8$  alkylcycloalkyl, oxo, halo amino, and  $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$ ;

$\text{R}^5$  is hydrogen, CN,  $\text{C}_1\text{-C}_8$  alkyl,  $\text{C}_2\text{-C}_8$  alkenyl,  $\text{C}_5\text{-C}_8$  alkylaryl,  $(\text{CH}_2)_n\text{NSO}_2\text{C}_1\text{-C}_8$  alkyl,  $(\text{CH}_2)_n\text{NSO}_2\text{phenyl}$ ,  $(\text{CH}_2)_n\text{NSO}_2\text{aryl}$ ,  $-\text{C}(\text{O})\text{C}_1\text{-C}_8$  alkyl, or  $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$  alkyl; and

$\text{R}^6$  and  $\text{R}^{6'}$  are each independently hydrogen,  $\text{C}_1\text{-C}_8$  alkyl, phenyl, aryl,  $\text{C}_1\text{-C}_8$  alkylaryl,  $\text{C}_1\text{-C}_8$  alkylcycloalkyl, or  $\text{C}_3\text{-C}_8$  cycloalkyl;

$\text{R}^7$  is hydrogen,  $\text{C}_1\text{-C}_8$  alkyl, phenyl, aryl,  $\text{C}_1\text{-C}_8$  alkylaryl, or  $\text{C}_3\text{-C}_8$  cycloalkyl, and wherein m is an integer from 1 to 8; and n is an integer from 0 to 8;

or a pharmaceutically acceptable salt, solvate, racemate, or enantiomer diastereomer or mixture of diastereomers thereof.

2. (Original) A compound according to Claim 1 wherein the group  $\text{Ar}^1$  is selected from the group consisting of: phenyl, benzothiophene, benzofuran, or naphthyl.

3. (Original) A compound according to Claim 1 wherein the group  $L^1$  is a linker selected from the group consisting of:  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-SCH_2-$ ,  $-OCH_2-$ ,  $-CH_2SCH_2-$ ,  $-CH_2OCH_2-$ , or  $-OCH_2CH_2SCH_2-$ .

4. (Original) A compound according to Claim 1 wherein  $Ar^3$  is an aromatic group selected from the group consisting of: indole, naphthyl, tetrahydronaphthyl, isoindolinone, isoquinolone, benzothiophene, or benzofuran.

5. (Original) A compound of Claim 1 wherein  $Ar^2$  is a 4 or 5 member aromatic group selected from the group consisting of: oxazole, oxadiazole, or furan.

6. (Original) A compound according to Claim 1 wherein the linker ( $L^2$ ) is:  $-CH_2-$ ,  $-CH_2CH_2-$ , or  $-CH_2CH_2CH_2-$ .

7. (Original) A compound according to Claim 1 wherein  $R^1$  and  $R^2$  combine with the nitrogen atom to form piperidinyl, pyrrolidinyl, azepine, or azetidiny.

8. (Original) A compound according to Claim 1 wherein  $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, methylcyclopentane, methylcyclohexane, phenyl, benzyl, cyclopentyl, cyclohexyl, methylcyclopropane and methylcyclobutane.

9. (Cancelled)

10. (Cancelled)


11. (Cancelled)

12. (Original) A compound according to Claim 1 wherein at least one of  $L^1$  and  $L^2$  has a chain length of 3 to 5 atoms.

13. (Previously Presented) A compound selected from the group consisting of: Dimethyl- $\{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl\}$ -amine oxalate,  
Dimethyl- $\{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-$

ylmethyl}-amine oxalate,  
{1-Methanesulfonyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,  
Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,  
{1-Methanesulfonyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,  
Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine,  
Dimethyl-{1-methyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,  
Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,  
Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine maleate,  
Dimethyl-{1-methyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,  
Dimethyl-{4-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-1-yl}-amine,  
Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-amine,  
2-(2-Phenoxy-ethylsulfanylmethyl)-5-(6-pyrrolidin-1-ylmethyl-naphthalen-2-yl)-[1,3,4]oxadiazole maleate,  
1-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-piperidine,  
2-(2-piperidinoethyl)-5-{2-[(2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one,  
and pharmaceutically acceptable salt, solvate, enantiomer, prodrug, diastereomer or mixture thereof.

14. (Original) A compound selected from the group consisting of:



or pharmaceutically acceptable salt, racemate, solvate, enantiomer or diastereomer or mixture of diastereomers thereof.

15. (Cancelled)

16. (Cancelled)

17. (Previously Presented) A method of treating obesity and Related Diseases comprising administering to a patient in need thereof a compound of Claim 1.

18. (Cancelled)

19. (Previously Presented) A pharmaceutical formulation comprising a compound of Claim 1 and a pharmaceutical carrier.

20. (Cancelled)